This document is a summary of the European public assessment report (EPAR) for Pandemrix. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pandemrix.
- What is Pandemrix?
Pandemrix is a vaccine that is given by injection. It contains parts of influenza (flu) viruses that have been inactivated. Pandemrix contains a flu strain called A/California/7/2009 (H1N1)v-like strain (X‑179A).
- What is Pandemrix used for?
Pandemrix is a vaccine to protect against flu caused by the A (H1N1)v 2009 virus. In people under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary. Pandemrix is given according to official recommendations.
The vaccine can only be obtained with a prescription.
- How is Pandemrix used?
Pandemrix is given as one dose, injected into the muscle of the shoulder or thigh. A second dose may be given after an interval of at least three weeks in children aged from six months to nine years. From 10 years of age the dose is 0.5 ml; younger children receive 0.25 ml per dose.
- How does Pandemrix work?
Pandemrix is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. Pandemrix contains small amounts of haemagglutinins (proteins from the surface) of a virus called A(H1N1)v 2009. The virus has first been inactivated (killed) so that it does not cause any disease.
When a person is given the vaccine, the immune system recognises the virus as ‘foreign’ and makes antibodies against it. The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again. This will help to protect against the disease caused by the virus.
Before use, the vaccine is made up by mixing together a suspension that contains the virus particles with a solvent. The resulting ‘emulsion’ is then injected. The solvent contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
- How has Pandemrix been studied?
Pandemrix was originally developed as a pandemic vaccine, to be used during the influenza A (H1N1) pandemic declared in June 2009. Six main studies have been carried out that looked at the ability of a two-dose schedule of the vaccine to trigger an immune response in the following groups (the numbers given are for those who received Pandemrix in the studies):
- healthy adults aged between 18 and 60 years (180 subjects in two studies);
- healthy elderly subjects over the age of 60 years (120 subjects in one study);
- healthy children (210 aged between three and 17 years, and 50 aged between six and 35 months, in three studies).
The studies in children also allowed the effectiveness of Pandemrix as a 0.5 ml dose to be compared with that of a 0.25 ml dose.
- What benefit has Pandemrix shown during the studies?
In all of the studies, the vaccine was shown to bring about protective levels of antibodies to a satisfactory level, in line with the criteria laid down by the CHMP.
The CHMP noted that a single dose was able to trigger immunity to a satisfactory level in adults (including the elderly), adolescents and children from 10 years of age. In children aged between six months and nine years, 0.25 ml doses were as effective as 0.5 ml doses.
- What is the risk associated with Pandemrix?
The most common side effects with Pandemrix (seen with more than 1 in 10 doses of the vaccine) are headache, arthralgia (joint pain), myalgia (muscle pain), swelling and pain at the site of the injection, shivering, increased sweating and fatigue (tiredness). For the full list of all side effects reported with Pandemrix, see the package leaflet.
Pandemrix must not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at trace (very low) levels in the vaccine, such as egg or chicken protein, ovalbumin (a protein in egg white), formaldehyde, gentamicin sulphate (an antibiotic) and sodium deoxycholate. Vaccination should be postponed in subjects with severe fever or an acute (short-lived) infection.
- Why has Pandemrix been approved?
The CHMP decided that Pandemrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Pandemrix was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, limited information was available at the time of approval. As the company had supplied the additional information requested, the ‘exceptional circumstances’ ended on 12 August 2010.
- Other information about Pandemrix
The European Commission granted a marketing authorisation valid throughout the European Union for Pandemrix on 20 May 2008.
For more information about treatment with Pandemrix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This EPAR was last updated on 24/04/2013 .
22/03/2013 Pandemrix -EMEA/H/C/000832 -IB/0064
|Name||Language||First published||Last updated|
|Pandemrix : EPAR - Product Information||BG = bălgarski||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||ES = español||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||CS = čeština||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||DA = dansk||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||DE = Deutsch||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||ET = eesti keel||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||EL = elliniká||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||EN = English||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||FR = français||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||IT = italiano||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||LV = latviešu valoda||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||LT = lietuvių kalba||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||HU = magyar||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||MT = Malti||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||NL = Nederlands||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||PL = polski||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||PT = português||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||RO = română||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||SK = slovenčina||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||SL = slovenščina||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||FI = suomi||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||SV = svenska||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||IS = Islenska||23/12/2009||24/04/2013|
|Pandemrix : EPAR - Product Information||NO = Norsk||23/12/2009||24/04/2013|
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Prophylaxis of influenza caused by A (H1N1)v 2009 virus. In persons under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary (see sections 4.4 and 4.8).
Pandemrix should be used in accordance with official guidance.
Changes since initial authorisation of medicine
Initial marketing-authorisation documents
|Name||Language||First published||Last updated|
|Pandemrix : EPAR - Public assessment report||(English only)||03/06/2008|
This medicine is approved for use in the European Union